Cost-effectiveness of oxaliplatin in the adjuvant treatment of colon cancer in Canada

Current Oncology

Volumn 17, Issue 1, 2010, Pages 17-24

  Attard, C L ^b   Maroun, J A ^c   Alloul, Karine ^a   Grima, D T ^b   Bernard, L M ^b  

^a SANOFI   (France)

^b Department of Data Analytics and Evidence Synthesis   (Canada)

^c OTTAWA REGIONAL CANCER CENTRE   (Canada)

Author keywords

5FU LV; Adjuvant; Chemotherapy; Colon cancer; Cost effectiveness; Oxaliplatin

Indexed keywords

DEXAMETHASONE; FLUOROURACIL; FOLINIC ACID; LOPERAMIDE; OXALIPLATIN; PROCHLORPERAZINE;

ABDOMINAL PAIN; ADULT; AGED; ALLERGIC REACTION; ARTICLE; CANADA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PATIENT; CANCER RELAPSE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG COST; DRUG UTILIZATION; FEBRILE NEUTROPENIA; HEALTH CARE COST; HISTOPATHOLOGY; HUMAN; INJECTION SITE REACTION; INTESTINE OBSTRUCTION; LEG THROMBOPHLEBITIS; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NAUSEA AND VOMITING; PARESTHESIA; PNEUMONIA; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TREATMENT OUTCOME; VOMITING;

EID: 75849148369     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v17i1.436     Document Type: Article

References (21)

1. Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2009. Toronto, ON: Canadian Cancer Society; 2009.
2. Gao RN, Neutel CI, Wai E. Gender differences in colorectal cancer incidence, mortality, hospitalizations and surgical procedures in Canada. J Public Health (Oxf) 2008;30:194-201.
3. André T, Boni C, Mounedji-Boudiaf L, et al. on behalf of the MOSAIC Investigators. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-51.
4. de Gramont A, Boni C, Navarro M, et al. Oxaliplatin/5FU/ lv in the adjuvant treatment of stage ii and stage III colon cancer: efficacy results with a median follow-up of 4 years [abstract 3501]. Proc Am Soc Clin Oncol 2005;23:246S. [Available online at: www.asco.org/ASCOv2/ Meetings/ Abstracts?&vmview=abst-detail-view&confID=34&abstrac tID=31256; cited December 7, 2009]
5. André T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009;27:3109-16.
6. Ontario, Ministry of Health and Long-Term Care, Ontario Public Drug Programs, Committee to Evaluate Drugs. Oxaliplatin (for Adjuvant Treatment of Colorectal Cancer): Recommendations and Reasons. Toronto, ON: Committee to Evaluate Drugs; 2008. [Available online at: www.health.gov.on.ca/english/ providers/program/drugs/ced/pdf/oxaliplatin-adjvuvant-colorectal. pdf; cited February 20, 2009]
7. Cancer Care Ontario (CCO). Home > Cancer System Quality Index > Colorectal Cancer > Treating Colon Cancer According to Guidelines > What's new this year? Figure 3: Results of a review of Stage III colon cancer patient charts conducted for cases resected in 2007-2008 showing treatment and reasons for non treatment [Web page]. Toronto, ON: CCO; 2009. [Available online at: csqi.cancercare.on.ca/cms/one.aspx?pageId=41160; cited December 15, 2009]
8. Cancer Care Ontario (CCO). Home > Prevention & Care > Treatment > Cancer Drugs > Drug Formulary > Chemotherapy Regimens > Gastrointestinal > Colorectal - Adjuvant > FOLFOX4. Toronto, ON: CCO; 2009. [Available online at: www. cancercare.on.ca/common/pages/ UserFile.aspx?fileId=12848; cited December 16, 2009]
9. Canadian Agency for Drugs and Technologies in Health (CADTH). Guidelines for the Economic Evaluation of Health Technologies: Canada. 3rd ed. Ottawa, ON: CADTH; 2006. [Available online at: www.cadth.ca/media/pdf/186-EconomicGuidelines-e. pdf; cited December 7, 2008]
10. Aballéa S, Chancellor JV, Raikou M, et al. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/ leucovorin in adjuvant treatment of stage III colon cancer in the US. Cancer 2007;109:1082-9.
11. Statistics Canada. Life Tables, Canada, Provinces and Territories [2000 to 2002]. Ottawa, ON: Statistics Canada; 2006. [Available online at: www.statcan.gc.ca/pub/84-537-x/t/ pdf/4198612-eng.pdf; cited December 7, 2009]
12. Van Den Brink M, Van Den Hout WB, Stiggelbout AM, et al. Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: a study of the Dutch Colorectal Cancer Group. J Clin Oncol 2004;22:244-53.
13. Ness RM, Holmes AM, Klein R, Dittus R. Utility valuations for outcome states of colorectal cancer. Am J Gastroenterol 1999;94:1650-7.
14. PPS Pharma. Sanofi-Aventis Canada: price list. In: Buyers Guide: Rest of Canada. January 2009 ed. Moncton, NB: PPS Pharma; 2009: 278.
15. World Health Organization (WHO). International Statistical Classification of Diseases and Related Health Problems. 10th rev. Geneva, Switzerland: WHO; 2007.
16. Maroun J, Ng E, Berthelot JM, et al. Lifetime costs of colon and rectal cancer management in Canada. Chronic Dis Can 2003;24:91-101.
17. Aballéa S, Boler A, Craig A, Wasan H. An economic evaluation of oxaliplatin for the adjuvant treatment of colon cancer in the United Kingdom (UK). Eur J Cancer 2007;43:1687-93.
18. National Health Service, National Institute for Health and Clinical Excellence (NICE). Capecitabine and Oxaliplatin in the Adjuvant Treatment of Stage III (Dukes' C) Colon Cancer. London, U.K.: NICE; 2006. [Available online at: www.nice.org. uk/nicemedia/pdf/TA100guidance.pdf; cited January 1, 2009]
19. Cassidy J, Douillard JY, Twelves C, et al. Pharmacoeconomic an- analysis of adjuvant oral capecitabine vs intravenous 5-FU/LV in Dukes' C colon cancer: the X-ACT trial. Br J Cancer 2006;94:1122-9.
20. Sargent DJ, Wieand HS, Haller DG, et al. Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol 2005;23:8664-70.
21. Goldberg RM, Sargent DJ, Morton RF, et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.